Immix Biopharma
IMMX
12 hedge funds and large institutions have $406K invested in Immix Biopharma in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 0 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
71% more funds holding
Funds holding: 7 → 12 (+5)
0.83% more ownership
Funds ownership: 1.32% → 2.15% (+0.83%)
15% less capital invested
Capital invested by funds: $475K → $406K (-$69K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$118K |
| 2 |
Renaissance Technologies
New York
|
+$59.1K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$41.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$16.8K |
| 5 |
State Street
Boston,
Massachusetts
|
+$9.62K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$74 |
IMMX Hedge Fund Activity: Q3 2022 in Review
12 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q3 2022, worth a combined $406K — down 15% from $475K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new IMMX positions and 0 closed out — a net gain of 5 holders — while 4 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $118K. The largest seller was Wells Fargo, cutting an estimated $74.
- 12 institutional investors held Immix Biopharma (IMMX) as of Q3 2022, up from 7 in Q2 2022.
- Funds reported $406K of Immix Biopharma stock for Q3 2022, down 15% quarter-over-quarter.
- 5 funds opened new Immix Biopharma positions in Q3 2022 and 0 closed out, a net change of +5 holders.
- The largest Immix Biopharma buyer in Q3 2022 was Vanguard Group, an estimated $118K added.
- The largest Immix Biopharma seller in Q3 2022 was Wells Fargo, an estimated $74 sold.
Based on aggregated 13F filings for Q3 2022.